Patents Assigned to Ade Therapeutics Inc.
  • Patent number: 10799622
    Abstract: The present disclosure relates to a method of treating or reducing adhesions in the peritoneum of a patient in need thereof. The method includes performing adhesiolysis on one or more adhesions involving the patient's peritoneum and/or one or more tissues or organs in the patient's peritoneal cavity; and administering to the peritoneum or the peritoneal cavity of the patient an effective amount of a composition comprising at least one glutamine source. The glutamine source is selected from one or more of L-glutamine, physiologically acceptable salts of L-glutamine, and dipeptides comprising L-glutamine.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: October 13, 2020
    Assignee: Ade Therapeutics, Inc.
    Inventor: Adebola O. E. Obayan
  • Patent number: 9011883
    Abstract: Intraperitoneal administration of glutamine to reduce adhesions in the peritoneum of a patient.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: April 21, 2015
    Assignee: Ade Therapeutics Inc.
    Inventor: Adebola O. E. Obayan
  • Publication number: 20140005116
    Abstract: Due to a long-standing interest in scar reduction, alanyl-glutamine was tested for ability to treat keloid scars, despite the difficulties associated with delivering compounds above a certain size threshold across the skin barrier to the dermis where new skin is formed. Surprisingly, it was found that a dermal application formulation of alanyl-glutamine was effective in reducing the severity and/or preventing the formation of keloid scars.
    Type: Application
    Filed: June 28, 2011
    Publication date: January 2, 2014
    Applicant: ADE THERAPEUTICS INC.
    Inventors: Adebola O.E. Obayan, Sanjeev Singh, Brenda Collen Joyce Yuzdepski
  • Publication number: 20130171209
    Abstract: Intraperitoneal administration of glutamine to reduce adhesions in the peritoneum of a patient.
    Type: Application
    Filed: February 27, 2013
    Publication date: July 4, 2013
    Applicant: Ade Therapeutics Inc.
    Inventor: Ade Therapeutics Inc.